Advertisement
Organisation › Details
Lupin Ltd.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment. Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019). For the financial year ended 31st March, 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. *
Group | Lupin (Group) | |
Industry | pharmaceutical | |
Industry 2 | DRUGS, GENERICS | |
Person | Gupta, Nilesh (Lupin 201909 Managing Director) | |
Region | Mumbai | |
Country | India | |
City | 400055 Mumbai | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 2,340,000,000 (sales, consolidated (2018FY) 2019-03-31) | |
Profit | 136,000,000 (2019-03-31) | |
* Document for »About Section«: Boehringer Ingelheim. (9/4/19). "Press Release: Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound". Ingelheim & Mumbai. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Lupin (Group)
- [1] Boehringer Ingelheim. (10/29/19). "Press Release: Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing". Ingelheim....
- [2] Boehringer Ingelheim. (9/4/19). "Press Release: Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound". Ingelheim & Mumbai....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top